You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
利民股份(002734.SZ):子公司取得新獸藥註冊證書
格隆匯 05-10 16:03

格隆匯 5 月 10日丨利民股份(002734.SZ)公佈,公司控股子公司河北威遠藥業有限公司近日獲得由農業農村部核發的二類《新獸藥註冊證書》,詳情如下:

泰地羅新為大環內酯類抗生素,具有廣譜殺菌作用,對部分革蘭氏陽性和革蘭氏陰性細菌均具有抗菌活性泰地羅新注射液主要用於預防和治療對泰地羅新敏感的胸膜肺炎放線桿菌、多殺性巴氏桿菌、支氣管敗血波氏桿菌、副豬嗜血桿菌等細菌引起的豬呼吸道疾病,其作用機理是與敏感菌的核蛋白體50s 亞基結合,抑制肽鏈的合成和延長,影響細菌蛋白質的合成。

目前我國廣泛使用的大環內酯類藥物主要是泰樂菌素和替米考星泰地羅新注射液具有動物專用、用量少、一次給藥全程治療等優點,解決了泰樂菌素和替米考星多次給藥的問題。

在新獸藥產品上市銷售前,相關單位將依據《獸藥管理條例》《獸藥產品批准文號管理辦法》規定及合同約定,開展產品批准文號申請工作,在取得獸藥產批准文號後,新獸藥產品方具備上市銷售條件。

新獸藥證書的取得,體現了公司“生產一代、研發一代、儲備一代”的科研方針,是公司持續重視科技創新、加大研發投入的結果。該產品作為公司新一代大環內酯類儲備產品,有助於豐富公司化學藥品產品序列,提高公司核心競爭能力。目前該產品尚不具備生產和上市條件,短期對於公司業績不會帶來明顯影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account